Abstract
OBJECTIVE: To determine whether high-flow nasal oxygen (HFNO) or noninvasive ventilator (NIV) can avoid invasive mechanical ventilation (IMV) in COVID-19-related acute respiratory distress syndrome (ADRS), and the outcome predictors of these modalities. DESIGN: Multicenter retrospective study conducted in 12 ICUs in Pune, India. PATIENTS: Patients with COVID-19 pneumonia who had PaO(2)/FiO(2) ratio <150 and were treated with HFNO and/or NIV. INTERVENTION: HFNO and/or NIV. MEASUREMENTS: The primary outcome was to assess the need of IMV. Secondary outcomes were death at Day 28 and mortality rates in different treatment groups. MAIN RESULTS: Among 1,201 patients who met the inclusion criteria, 35.9% (431/1,201) were treated successfully with HFNO and/or NIV and did not require IMV. About 59.5% (714/1,201) patients needed IMV for the failure of HFNO and/or NIV. About 48.3, 61.6, and 63.6% of patients who were treated with HFNO, NIV, or both, respectively, needed IMV. The need of IMV was significantly lower in the HFNO group (p <0.001). The 28-day mortality was 44.9, 59.9, and 59.6% in the patients treated with HFNO, NIV, or both, respectively (p <0.001). On multivariate regression analysis, presence of any comorbidity, SpO(2) <90%, and presence of nonrespiratory organ dysfunction were independent and significant determinants of mortality (p <0.05). CONCLUSIONS: During COVID-19 pandemic surge, HFNO and/or NIV could successfully avoid IMV in 35.5% individuals with PO(2)/FiO(2) ratio <150. Those who needed IMV due to failure of HFNO or NIV had high (87.5%) mortality. HOW TO CITE THIS ARTICLE: Jog S, Zirpe K, Dixit S, Godavarthy P, Shahane M, Kadapatti K, et al. Noninvasive Respiratory Assist Devices in the Management of COVID-19-related Hypoxic Respiratory Failure: Pune ISCCM COVID-19 ARDS Study Consortium (PICASo). Indian J Crit Care Med 2022;26(7):791-797.